Knocking Down Breast Cancer Resistance Protein (Bcrp) by Adenoviral Vector-Mediated RNA Interference (RNAi) in Sandwich-Cultured Rat Hepatocytes: A Novel Tool To Assess the Contribution of Bcrp to Drug Biliary Excretion
- 23 December 2008
- journal article
- research article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 6 (1) , 134-143
- https://doi.org/10.1021/mp800100e
Abstract
BCRP transports numerous drugs/derived metabolites and toxins, and exhibits overlapping substrate specificity with P-glycoprotein (P-gp) and multidrug resistance-associated protein 2 (MRP2). Assessing the contribution of BCRP to drug/metabolite biliary excretion in intact hepatocytes remains a challenge. Current studies were designed to develop a novel in vitro tool to specifically assess the contribution of Bcrp to drug biliary excretion. Adenoviral vectors expressing short hairpin (sh) RNA targeting Bcrp (Ad-si01Bcrp) or a nontarget control (Ad-siNT) were packaged and infected into sandwich-cultured rat hepatocytes (SCRH). Protein levels were detected by immunoblot. Biliary excretion index (BEI) and in vitro biliary clearance (Clbiliary) of nitrofurantoin (BCRP substrate) and digoxin (P-gp substrate) were compared among noninfected, Ad-siNT- and Ad-si01Bcrp-infected SCRH. shRNA targeting Bcrp efficiently knocked down Bcrp in SCRH, while levels of other transport proteins (P-gp, Mrp2, Bsep, Mrp4 and Oatp1a1) were unaffected. In SCRH exhibiting Bcrp knockdown, cellular accumulation of nitrofurantoin was increased markedly and nitrofurantoin BEI and in vitro Clbiliary were decreased to 11% and 14% of control, respectively. Digoxin values were unaffected by knockdown of Bcrp. Results indicated that Bcrp in SCRH contributed predominantly to nitrofurantoin biliary excretion, but played a negligible role in digoxin biliary excretion. In summary, Bcrp knockdown in SCRH is the first in vitro model utilizing intact hepatocytes to assess the contribution of Bcrp to the biliary excretion of drugs. This approach may be useful in predicting drug−drug interactions in biliary excretion and the consequence of impaired BCRP function on the hepatic exposure of drugs/derived metabolites.Keywords
This publication has 60 references indexed in Scilit:
- Use of Sandwich-Cultured Human Hepatocytes to Predict Biliary Clearance of Angiotensin II Receptor Blockers and HMG-CoA Reductase InhibitorsDrug Metabolism and Disposition, 2009
- TheABCG2C421A polymorphism does not affect oral nitrofurantoin pharmacokinetics in healthy Chinese male subjectsBritish Journal of Clinical Pharmacology, 2008
- Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitorInternational Journal of Pharmaceutics, 2007
- The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2)British Journal of Pharmacology, 2007
- Radixin Is Required to Maintain Apical Canalicular Membrane Structure and Function in Rat HepatocytesGastroenterology, 2006
- Effect of ABCG2 genotype on the oral vioavailability of topotecanCancer Biology & Therapy, 2005
- Functional Characterization of the Human Multidrug Transporter, ABCG2, Expressed in Insect CellsBiochemical and Biophysical Research Communications, 2001
- Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.Journal of Clinical Investigation, 1995
- P‐glycoprotein stability is affected by serum deprivation and high cell density in multidrug‐resistant cellsJournal of Cellular Physiology, 1995
- The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxinBiochemical and Biophysical Research Communications, 1992